恒瑞医药涨超3% EZH2抑制剂泽美妥司他片获药品注册批准

Core Viewpoint - Heng Rui Medicine (600276) has received conditional approval from the National Medical Products Administration for its innovative drug, Zemeituosita Tablets (SHR2554), aimed at adult patients with relapsed or refractory peripheral T-cell lymphoma (R/RPTCL) who have previously undergone at least one line of systemic treatment [1] Group 1: Company Developments - Heng Rui Medicine's stock rose by 3.21%, reaching HKD 82.05, with a trading volume of HKD 206 million [1] - The Zemeituosita Tablets are the first EZH2 inhibitor developed independently in China, marketed under the name Airi Jing [1] - The company has invested approximately CNY 213 million in the research and development of Zemeituosita Tablets to date [1] Group 2: Product Details - Zemeituosita Tablets effectively inhibit both wild-type and mutant EZH2 enzyme activity by precisely binding to the SET catalytic domain of EZH2, blocking the abnormal generation of H3K27me3 [1] - The drug reactivates tumor suppressor genes and initiates the apoptosis program in tumor cells, while also improving the tumor microenvironment and restoring the body's immune surveillance and clearance capabilities against tumor cells [1]